Showing posts with label review. Show all posts
Showing posts with label review. Show all posts

Saturday, September 28, 2013

0 The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis

Open Access


Research article


The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis



Melinde RS Boland, Apostolos Tsiachristas, Annemarije L Kruis, Niels H Chavannes and Maureen PMH Rutten-van Mölken










For all author emails, please log on.








BMC Pulmonary Medicine 2013, 13:40 doi:10.1186/1471-2466-13-40

Published: 3 July 2013





Abstract (provisional)


Background


There is insufficient evidence of the cost-effectiveness of Chronic Obstructive Pulmonary Disease (COPD) Disease Management (COPD-DM) programs. The aim of this review is to evaluate the economic impact of COPD-DM programs and investigate the relation between the impact on healthcare costs and health outcomes. We also investigated the impact of patient-, intervention, and study-characteristics.

Methods


We conducted a systematic literature review to identify cost-effectiveness studies of COPD-DM. Where feasible, results were pooled using random-effects meta-analysis and explorative subgroup analyses were performed.

Results


Sixteen papers describing 11 studies were included (7 randomized control trials (RCT), 2 pre-post, 2 case–control). Meta-analysis showed that COPD-DM led to hospitalization savings of [euro sign]1060 (95% CI: [euro sign]2040 to [euro sign]80) per patient per year and savings in total healthcare utilization of [euro sign]898 (95% CI: [euro sign]1566 to [euro sign]231) (excl. operating costs). In these health economic studies small but positive results on health outcomes were found, such as the St Georges Respiratory Questionnaire (SGRQ) score, which decreased with 1.7 points (95% CI: 0.5-2.9). There was great variability in DM interventions-, study- and patient-characteristics. There were indications that DM showed greater savings in studies with: severe COPD patients, patients with a history of exacerbations, RCT study design, high methodological quality, few different professions involved in the program, and study setting outside Europe.

Conclusions


COPD-DM programs were found to have favourable effects on both health outcomes and costs, but there is considerable heterogeneity depending on patient-, intervention-, and study-characteristics.






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.



Wednesday, September 25, 2013

0 The acute and long-term management of anaphylaxis: protocol for a systematic review

Open AccessStudy protocol

The acute and long-term management of anaphylaxis: protocol for a systematic review



Sangeeta Dhami, Sukhmeet S Panesar, Tamara Rader, Antonella Muraro, Graham Roberts, Margitta Worm and Aziz Sheikh










For all author emails, please log on.








Clinical and Translational Allergy 2013, 3:14 doi:10.1186/2045-7022-3-14

Published: 10 April 2013







Abstract (provisional)


Background


The European Academy of Allergy and Clinical Immunology is in the process of developing its Guideline for Food Allergy and Anaphylaxis, and this systematic review is one of seven inter-linked evidence syntheses that are being undertaken in order to provide a state-of-the-art synopsis of the current evidence base in relation to epidemiology, prevention, diagnosis and clinical management and impact on quality of life, which will be used to inform clinical recommendations.

The aims of this systematic review will be to assess the effectiveness of interventions for the acute management of anaphylaxis, and pharmacological and non-pharmacological approaches for the long-term management of anaphylaxis.

Methods


A highly sensitive search strategy has been developed, and validated study design filters will be applied to retrieve all articles pertaining to the management of anaphylaxis from electronic bibliographic databases. We will systematically review the literature on the acute management of anaphylaxis by assessing the effectiveness of epinephrine, H1-antihistamines (versus placebo), systemic glucocorticosteroids, methylxanthines or any other treatments for the emergency management of people experiencing anaphylaxis. The main interventions that have been studied in the context of long-term management are anaphylaxis management plans and allergen-specific immunotherapy.

Discussion


There is at present little in the way of robust evidence to guide decisions on the acute and/or long-term management of anaphylaxis. Given the risk of death and the considerable morbidity associated with anaphylaxis these evidence gaps need to be filled wherever possible; this systematic review will make a start in this area.




The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.






Tuesday, September 17, 2013

0 A review on guidelines for management and treatment of common variable immunodeficiency



Summary


June 2013, Vol. 9, No. 6, Pages 561-575 , DOI 10.1586/eci.13.30

(doi:10.1586/eci.13.30)





Review

  

A review on guidelines for management and treatment of common variable immunodeficiency



Hassan Abolhassani1, Babak Torabi Sagvand1, Tahaamin Shokuhfar1, Babak Mirminachi1, Nima Rezaei1,2 and Asghar Aghamohammadi*1


* Author for correspondence



Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adults. As symptoms of CVID are usually heterogeneous and unspecific, diagnosis and follow-up of CVID can be challenging. In light of this, a broad review of advances in management and treatment of CVID is performed here in order to reach a distinct protocol. However, it should be noted that owing to the nature of the disease, it can only be treated symptomatically but not cured. There is little evidence to guide appropriate or universal guidelines to improve the current status of management of the disease. The most satisfactory treatments of CVID could be achieved by the use of immunoglobulin replacement, antibiotics, immunosuppressants and hematopoietic stem cell transplantation. This review is written based on the importance of clinical surveillance of asymptomatic CVID cases and early recognition of different clinical complications. Moreover, for each complication, appropriate interventions for improving outcomes are mentioned.







Full TextPDF (4044 KB)PDF Plus (4166 KB)